Cantargia
Develops antibody therapies targeting IL1RAP for cancer and inflammatory diseases.
CANTA | ST
Overview
Corporate Details
- ISIN(s):
- SE0006371126 (+3 more)
- LEI:
- 549300GKWRT7RXI4VS85
- Country:
- Sweden
- Address:
- Scheelevägen 27, 223 63 Lund
- Website:
- https://cantargia.com/en/
- Sector:
- Manufacturing
Description
Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-07-25 15:00 |
Cantargia rapporterar nya prekliniska effektdata för CAN10 som stödjer utveckli…
|
Swedish | 188.8 KB | ||
| 2022-07-22 14:15 |
Cantargia publishes prospectus and certain new financial information included i…
|
English | 228.0 KB | ||
| 2022-07-22 14:15 |
Cantargia offentliggör prospekt samt viss ny finansiell information som återfin…
|
Swedish | 223.2 KB | ||
| 2022-07-21 11:45 |
Extraordinary general meeting in Cantargia AB (publ)
|
English | 154.9 KB | ||
| 2022-07-21 11:45 |
Extra bolagsstämma i Cantargia AB (publ)
|
Swedish | 153.3 KB | ||
| 2022-07-19 14:48 | English | 33.9 KB | |||
| 2022-07-18 08:30 |
Cantargia announces the terms of its fully covered rights issue
|
English | 239.0 KB | ||
| 2022-07-18 08:30 |
Cantargia offentliggör villkoren för den fullt garanterade företrädesemissionen
|
Swedish | 234.5 KB | ||
| 2022-07-08 14:00 |
Cantargia appoints Dr. Dominique Tersago as Chief Medical Officer
|
English | 192.3 KB | ||
| 2022-07-08 14:00 |
Cantargia utser Dr. Dominique Tersago till Chief Medical Officer
|
Swedish | 184.8 KB | ||
| 2022-06-21 23:45 |
Kallelse till extra bolagsstämma i Cantargia AB (publ)
|
Swedish | 192.5 KB | ||
| 2022-06-21 23:45 |
Notice of extraordinary general meeting in Cantargia AB (publ)
|
English | 193.7 KB | ||
| 2022-06-21 23:30 |
Cantargia resolves on a fully covered rights issue of approximately SEK 250 mil…
|
English | 244.2 KB | ||
| 2022-06-21 23:30 |
Cantargia beslutar om en fullt garanterad företrädesemission om cirka 250 miljo…
|
Swedish | 239.8 KB | ||
| 2022-05-26 23:00 |
Cantargia presents clinical interim results at ASCO 2022 highlighting the poten…
|
English | 202.6 KB |
Automate Your Workflow. Get a real-time feed of all Cantargia filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cantargia
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cantargia via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-19 | Nedjad Losic | Other | Buy | 21,375 | 33,131.25 SEK |
| 2025-01-02 | Antonius Franciscus Berkien | Other | Other | 21,621 | 39,998.85 SEK |
| 2024-12-20 | Göran Forsberg | Other | Other | 152,206 | 281,581.10 SEK |
| 2024-12-20 | Nedjad Losic | Other | Other | 12,875 | 23,818.75 SEK |
| 2024-12-09 | Antonius Franciscus Berkien | Other | Buy | 3,741 | 6,733.80 SEK |
| 2023-01-19 | Nedjad Losic | Other | Buy | 3,918 | 29,110.74 SEK |
| 2023-01-17 | Göran Forsberg | Other | Buy | 17,000 | 140,250.00 SEK |
| 2023-01-17 | Bengt Jöndell | Other | Buy | 6,500 | 54,665.00 SEK |
| 2022-07-28 | Göran Forsberg | Other | Other | 91,765 | 344,118.75 SEK |
| 2022-07-28 | Thoas Fioretos | Other | Other | 78,400 | 294,000.00 SEK |
Peer Companies
